Larimar Therapeutics (LRMR) Cash & Equivalents (2016 - 2020)
Historic Cash & Equivalents for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $101.3 million.
- Larimar Therapeutics' Cash & Equivalents rose 13376.79% to $101.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $101.3 million, marking a year-over-year increase of 13376.79%. This contributed to the annual value of $1.0 million for FY2019, which is 9795.46% down from last year.
- Per Larimar Therapeutics' latest filing, its Cash & Equivalents stood at $101.3 million for Q3 2020, which was up 13376.79% from $112.7 million recorded in Q2 2020.
- Larimar Therapeutics' 5-year Cash & Equivalents high stood at $112.7 million for Q2 2020, and its period low was $1.0 million during Q4 2019.
- Its 5-year average for Cash & Equivalents is $41.1 million, with a median of $37.2 million in 2019.
- As far as peak fluctuations go, Larimar Therapeutics' Cash & Equivalents crashed by 9795.46% in 2019, and later skyrocketed by 20255.91% in 2020.
- Over the past 5 years, Larimar Therapeutics' Cash & Equivalents (Quarter) stood at $32.4 million in 2016, then rose by 26.04% to $40.8 million in 2017, then rose by 20.98% to $49.3 million in 2018, then plummeted by 97.95% to $1.0 million in 2019, then skyrocketed by 9940.44% to $101.3 million in 2020.
- Its last three reported values are $101.3 million in Q3 2020, $112.7 million for Q2 2020, and $39.0 million during Q1 2020.